Express Pharma

APRIL 24, 2023

GlaxoSmithKline Pharmaceuticals (GSK) announced the launch of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in India, for the prevention of shingles (herpes zoster) and post-herpetic neuralgia in adults aged 50 years and above. Shingrix is a non-live, recombinant subunit vaccine to be given intramuscularly in two doses.

Vaccines 97

Vaccines Diabetes Immunization Immunity 97

European Pharmaceutical Review

OCTOBER 21, 2022

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. At week 28, the study assessed the vaccine’s safety and levels of anti-HBV surface antibodies (HBsAbs).

Vaccines 96

Vaccines Immunization Immunity 96

Pharmaceutical Technology

SEPTEMBER 15, 2022

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccines 108

Vaccines Drug Pricing Biosimilars Documentation 108

Express Pharma

JANUARY 23, 2025

This period included the implementation of novel designation types: qualified infectious disease product designation (in 2012), breakthrough therapy (2013), rare pediatric drug designation (2014), and regenerative medicine advanced therapy designation (2017). In 2020, the number of designations awarded reached a peak of 694.

Vaccines 104

Vaccines Drug Development 104

STAT

OCTOBER 27, 2022

The investigation began in February and covers 2017, 2018, and 2019. The Italian branch allegedly sent the capital to foreign affiliates linked to a units based in Delaware called Pfizer Production and Pfizer Manufacturing. Continue to STAT+ to read the full story…

Packaging 246

Packaging Vaccines 246

Express Pharma

JUNE 9, 2024

GSK announced that the US FDA has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 to 59 years of age who are at increased risk. This antigen is combined with GSK’s proprietary AS01E adjuvant.

Vaccines 111

Vaccines Immunization Immunity Diabetes 111

pharmaphorum

FEBRUARY 16, 2021

A news agency is claiming that North Korea launched a cyber-attack on Pfizer in a bid to steal information about its BioNTech-partnered COVID-19 vaccine, citing South Korea’s National Intelligence Service (NIS). Staff are working faster, harder and longer hours than ever before,” says Jack Garnsey of cybersecurity specialist VIPRE. “In

Vaccines 111

Vaccines Hospitals 111

European Pharmaceutical Review

MARCH 27, 2023

The research includes historic market data from 2017 to 2021, using 2022 as the base year. million in 2017 and continued to grow until 2021. It covers various testing methods such as growth-based, nucleic-acid-based and viability-based. The segment was valued at $1,492.53

Compounding 115

Compounding Vaccines 115

pharmaphorum

MAY 9, 2022

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV). The aim of both alliances was to study MVA-BN in a prime-boost vaccine regimen with Janssen’s own AdVac vaccine technology.

Vaccines 52

Vaccines 52

pharmaphorum

JULY 30, 2021

Takeda has decided development of its norovirus vaccine candidate outside Japan will be more efficient if it is spun out into a dedicated company. The post Takeda spins norovirus vaccine out into separate company appeared first on. In 2019, it agreed a $170 million deal to buy back into the company’s platform.

Vaccines 52

Vaccines 52

European Pharmaceutical Review

OCTOBER 30, 2023

Vaccitech’s Chief Business Officer, Graham Griffiths, discusses key learnings in drug and vaccine development , the challenges of preparing for the unknown, and how strategic collaboration is imperative to achieve faster and more equitable outcomes – if and when another pandemic strikes.

Vaccines 114

Vaccines Drug Development 114

Express Pharma

MARCH 20, 2023

India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). The Indian government will float a global tender in April 2023 to procure HPV vaccines. per cent from 0.43 million in 2021 to 0.54 million in 2030.

Vaccines 52

Vaccines Immunization Immunity 52

pharmaphorum

MAY 31, 2022

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. The post GSK bolsters vaccines division with $3.3bn swoop on Affinivax appeared first on. GlaxoSmithKline has agreed a $3.3

Vaccines 52

Vaccines Immunization Immunity 52

pharmaphorum

MARCH 2, 2022

Pfizer’s vaccine for Clostridium difficile (C. Top-line efficacy for the vaccine was 49% at 12 months, 47% at 24 months and 31% at final analysis, said the drugmaker, which was forced to carry out the assessment after 42 cases of CDI, fewer than the 66 cases laid out in the trial protocol. With no approved vaccines to date, C.

Vaccines 52

Vaccines Hospitals 52

Pharmaceutical Technology

MAY 15, 2023

In May 2023, GSK had its RSV vaccine approved for older adults , with Pfizer having a PDUFA date for its vaccine intended for the same population at the end of May. Moderna and Johnson & Johnson are also at Phase III trial stages for respective mRNA and recombinant vector vaccines.

Vaccines 98

Vaccines Hospitals 98

Pharmaceutical Technology

AUGUST 1, 2022

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 93

pharmaphorum

JANUARY 6, 2022

mRNA emerged as the most important new technology for the biopharma sector in 20021, as COVID-19 vaccines from Pfizer/BioNTech and Moderna – which both use lipid nanoparticles for delivery – quickly became the mainstay of many immunisation programmes around the world. The unit contributed almost €3.4 billion in the first nine months of 2021.

Vaccines 98

Vaccines 98

The Pharmacist

DECEMBER 13, 2024

had hepatitis C, compared with 26% in 2017. The rate of chronic hepatitis C infections for people who inject drugs has fallen in the last six years, according to the latest data from the UK Health Security Agency (UKHSA). A survey of people who inject drugs found 7.8%

Vaccines 90

Vaccines 90

pharmaphorum

DECEMBER 21, 2020

More than 1,000 NHS patients have booked flu vaccinations using a virtual assistant as part of a pilot project in the south east of England. Launched in 2017, the free-to-use Ask NHS app lets users easily check symptoms, book clinician appointments, access self-care resources, and connect with live video consultations.

Vaccines 75

Vaccines 75

European Pharmaceutical Review

MAY 15, 2023

Thomas Triomphe, Executive Vice President of Vaccines at Sanofi shared: “The HARMONIE data demonstrate the real-world impact nirsevimab has on paediatric hospitalisations.” Agreed in March 2017, AstraZeneca leads development and manufacturing activities, and Sanofi leads commercialisation activities. percent.

Vaccines 104

Vaccines Hospitals 104

PharmaTech

MAY 16, 2023

The first CleanCap analog was launched in 2017, and since then, the capping technology has been incorporated in one of the first commercially approved COVID-19 vaccines.

Vaccines 52

Vaccines 52

Express Pharma

JUNE 15, 2024

India, synonymous with the “pharmacy of the world” has rightfully earned the title, owing to its remarkable contribution in supplying 20 per cent of the global generic medicines, along with 60 per cent of the total vaccine demand worldwide.

Vaccines 111

Vaccines Generic Medicine 111

FDA Law Blog: Biosimilars

FEBRUARY 4, 2025

2014) June 2016 Vaxchora (Pax Vax Bermuda) Cholera vaccine for travelers $ 290 (June 2016) Aug 2017 Benznidazole (Chemo Research) Chagas disease UNK June 2018 Moxidectin (Medicines Devt for Global Health) Onchocerciasis, or river blindness UNK (May 2019) July 2018 Krintafel (GSK) P.

Vaccines 52

Vaccines 52

European Pharmaceutical Review

MAY 2, 2024

“The scale and speed of impact seen after Beyfortus’ introduction demonstrates the strength of all-infant immunisation strategies against RSV in babies,” summarised Thomas Triomphe , Executive Vice President, Vaccines, Sanofi.

Hospitals 122

Hospitals Immunization Immunity Vaccines 122

pharmaphorum

APRIL 29, 2021

billion and its vaccines business has also been hit by a 32% slump as people put off getting vaccinated against shingles with its lead product Shingrix during the pandemic. Pharma sales were down 12% compared with last year’s Q1 to £3.9

Vaccines 72

Vaccines 72

pharmaphorum

NOVEMBER 6, 2022

The new drug will reach the market ahead of RSV vaccines that are designed to protect newborns in the months after birth by vaccinating expectant mothers, who pass on antibodies against the virus in the womb. AZ and Sanofi say they hope to launch the antibody next autumn, in time for the 2023/24 RSV season.

Vaccines 64

Vaccines Labelling 64

pharmaphorum

MAY 11, 2022

If approved, nirsevimab would provide a new option for managing RSV, ahead of the possible rollout of vaccines that could be used to protect young children. Despite the RSV vaccine threat, analysts at GlobalData have predicted that nirsevimab could reach $3 billion in annual revenue by 2030, assuming a launch next year.

Vaccines 64

Vaccines 64

Express Pharma

AUGUST 10, 2024

The spectrum of such products includes new chemical entities (NCE), new drugs with new indications or new routes of administration or new dosage forms, modified or sustained release formulations, novel drug delivery forms, vaccines, medical devices, and in-vitro diagnostic medical devices.

Drug Development 105

Drug Development Vaccines Dosage Documentation 105

pharmaphorum

SEPTEMBER 18, 2020

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 Seroquel IR’s patent expired in 2012, while Seroquel XR’s expired in 2017. The AZD1222 vaccine was invented by the University of Oxford and its spin-out company Vaccitech, then later licensed by AZ.

Vaccines 116

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 116

pharmaphorum

JULY 14, 2021

Already facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Affinivax reported positive phase 2 results with its ASP3772 candidate – plus a new breakthrough designation from the FDA. That is equivalent to 14% of Pfizer’s total revenues.

Vaccines 52

Vaccines Immunization Immunity 52

pharmaphorum

SEPTEMBER 16, 2022

The former blockbuster – first approved back in 1998 – is still making solid sales despite losing patent protection, with AZ booking $410 million from the drug last year, but are expected to drop sharply once Beyfortus and vaccines for RSV prevention reach the market. Both vaccines are also being tested in older adults.

Vaccines 59

Vaccines Immunization Immunity 59

Pharmaceutical Technology

NOVEMBER 7, 2022

AstraZeneca Vaccines and Immune Therapies executive vice-president Iskra Reic said: “Beyfortus is the first single-dose preventative option against the respiratory syncytial virus to gain approval in Europe and is also the first and only preventative option approved for a broad infant population. . “The

Dosage 64

Dosage Immunization Immunity Vaccines 64

pharmaphorum

MARCH 26, 2021

In the space of 24 hours, Slaoui (61) exited as chairman of US vaccine developer Vaxcyte at the request of the company, and resigned from his role at chief scientific officer at recently-formed Centessa Pharma as well as from a partner position at European venture capital firm Medicxi.

Vaccines 52

Vaccines 52

pharmaphorum

OCTOBER 26, 2020

Strategies include different options focused on health maintenance, such as vaccination programmes, smoking cessation services, support for physical activity, and access to technologies that support early detection of diseases. Figure 1: OECD average of public spending on health (Source: OECD ). per person in the US) and is widely adopted.

Vaccines 130

Vaccines 130

pharmaphorum

MAY 18, 2021

David Cumming, investment chief at shareholder Aviva, noted in an interview with Radio 4 that Elliott Management had been able to build its stake because of GSK’s slumping share price, which is 15% down since Walmsley took charge in 2017. “It Scheduled to complete in mid-2022 the new GSK will be focused on pharmaceuticals and vaccines.

Vaccines 59

Vaccines 59

pharmaphorum

APRIL 4, 2022

Until now, AXA Investment Managers has been focused more on the delivery end of health care – health centres and private hospitals, for example – but the new strategy is directed at four key areas, including biopharma, vaccines, medical devices and diagnostics companies.

Vaccines 59

Vaccines Hospitals 59

pharmaphorum

JUNE 28, 2021

GlaxoSmithKline meanwhile is taking a different approach, developing a maternal vaccine designed to impart protection to the infant that the company thinks could be a £3 billion ($4.2 Last year, sales were around $320 million. billion) product at its peak.

Inpatient 66

Inpatient Vaccines 66